CompletedNCT04202627
Biomarker Development in LGMD2i
Studying Limb-girdle muscular dystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ML Bio Solutions, Inc.
- Principal Investigator
- Nicholas E Johnson, MD, MDVirginia Commonwealth University
- Enrollment
- 101 enrolled
- Eligibility
- 10-65 years · All sexes
- Timeline
- 2019 – 2022
Study locations (11)
- University of California Irvine, Irvine, California, United States
- University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
- University of Florida, Gainesville, Florida, United States
- University of Iowa, Iowa City, Iowa, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- Kennedy Krieger Institute, Baltimore, Maryland, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Atrium Health, Charlotte, North Carolina, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- Virginia Commonwealth University, Richmond, Virginia, United States
- Copenhagen Neuromuscular Center, Copenhagen, Denmark
Collaborators
Virginia Commonwealth University
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04202627 on ClinicalTrials.govOther trials for Limb-girdle muscular dystrophy
Additional recruiting or active studies for the same condition.